Home  /  Resource Library  /  Rituximab, interferon-alfa-2b and dose dense CVP is highly efficient in patients with FLIPI greater than 2 follicular lymphoma. Final results of the LNH-PRO‐05 study

Rituximab, interferon-alfa-2b and dose dense CVP is highly efficient in patients with FLIPI greater than 2 follicular lymphoma. Final results of the LNH-PRO‐05 study

Results of a phase II study involving rituximab combined with interferon